05-Dec-2019 - VEROVACCiNES GmbH

Biotech start-up Verovaccines concludes international pharma cooperation agreement

The goal is to develop and commercialize novel, cost-effective vaccines for animal health

The Verovaccines GmbH has signed the first cooperation agreement with a Japanese pharmaceutical partner for the joint development of an animal vaccine. This cooperation documents a significant step forward in the company’s development and the clear interest of market participants in vaccines based on the novel technology platform. In the Seed Investment Round, the company raised seven-figure funding from High-Tech Gründerfonds, Business Angels and the founders as well as funding from the German government’s GO-Bio programme.

Verovaccines develops novel vaccines for animal health using a proprietary technology platform based on K. lactis milk yeast. In several previous vaccine tests, good results were achieved in the target animal pig (Proof of Concept) with regard to protection against a viral pathogen. The vaccines are very cost-effective to manufacture, highly efficacious, easy to combine, heat-stable and safe to manufacture and use. All in all, these properties represent important unique selling points on the international vaccine market. The application of the technology platform offers urgently needed solutions for a large number of infectious diseases in animals.

Managing Director Dr. Hanjo Hennemann: “This pharmaceutical cooperation demonstrates the validity of the technology platform and the added value that our vaccines have in the market through the proof of concept results already achieved. We look forward to further cooperate with our partner”.

The Senior Investment Manager of the High-Tech Gründerfonds, Dr. Philipp Rittershaus, adds: “We are pleased about the successful development of the vaccination platform, which we have accompanied since the foundation phase. The successful development work of the team is positively confirmed by the industry and market interest”.

Yeast-based vaccines

The vaccines of Verovaccines GmbH are based on a proprietary and patent-protected technology platform using the milk yeast Kluyveromyces lactis. Several different immunity-triggering proteins (antigens) can be produced in one yeast cell to generate cost-effective combination vaccines. The vaccines contain complete, killed yeast cells that are made heat-stable by freeze-drying and can therefore be stored at room temperature. The technology is safely validated by proof of concept in three vaccine programs in the respective target animals. Verovaccines is using its broad technology to develop a product pipeline of seven vaccines against pathogens in pigs, cattle, poultry and fish.

Facts, background information, dossiers
  • Companies


    VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target ... more

More about High-Tech Gründerfonds Management
  • News

    Novel laser technology for biomedicine

    High-Tech Gründerfonds (HTGF) invests in the start-up Twenty-One Semiconductors (21S) as part of a first round of financing. The spin-off from the University of Stuttgart produces semiconductor-based laser crystals for biomedical applications. These crystals enable the realization of laser ... more

    Cell therapy against transplant rejection

    ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, has successfully closed its Series A financing. A consortium led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank ... more

    Advance Gene Therapy Pipeline for Musculoskeletal Diseases

    GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has raised €5.4 million in Series A financing and €3.65 million non-dilutive funding bringing the total amount raised to €9.05 million. The Series A ... more